MDA

psilodex.org/m/mda · data v2026.10.02

Clinical contraindication: Relative; Substantial clinical concern; the literature treats it as a reason for caution or deferral.
Best available evidence: Mechanism only
Half-life: Not recorded

Named in state rules?

CONot named

ORNot named

NMPending

Cite asPsilodex: mda · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

Releases serotonin, dopamine and norepinephrine like MDMA. In a controlled study it robustly raised heart rate and blood pressure, with MDMA-like and psychedelic-like effects lasting about 8 hours. Added serotonergic and cardiovascular load with psilocybin is expected.

Human data with psilocybin: None known: no published human data with psilocybin

Evidence types on this record

ThMechanism only (theoretical)

02 Pharmacology relevant to psilocybin

2 listed · counted on reports

Serotonergic: Increases serotonin activity, for example by blocking its reuptake or releasing it. Psilocybin acts on serotonin receptors, so effects can add together. With antidepressant use, the psilocybin response can be weaker. Sources [2]
Raises blood pressure or heart rate: Raises blood pressure or heart rate. Psilocybin raises both for several hours, so the effects can add. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-02

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

Baggott MJ, Garrison KJ, Coyle JR, et al. Effects of the psychedelic amphetamine MDA (3,4-methylenedioxyamphetamine) in healthy volunteers. J Psychoactive Drugs 2019;51(2):108–117. — 1.4 mg/kg oral MDA: robust HR and BP increases; effects elevated at 8 h
Brandt SD, Walters HM, Partilla JS, et al. The psychoactive aminoalkylbenzofuran derivatives, 5-APB and 6-APB, mimic the effects of 3,4-methylenedioxyamphetamine (MDA) on monoamine transmission in male rats. Psychopharmacology (Berl) 2020;237(12):3703–3714. — MDA is a substrate-type releaser at SERT, DAT and NET; raised brain serotonin (rats)

Record history

v2026.10.02First published.
2026-10-02Last reviewed against its sources.

Report an error in this record →